Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct 16:56:101532.
doi: 10.1016/j.gore.2024.101532. eCollection 2024 Dec.

Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Anna Babkova  1 , Helena Robova  1 , Hana Malikova  2 , Jana Drozenova  3 , Tomas Pichlik  1 , Michael J Halaska  1 , Lukas Rob  1
Affiliations
Case Reports

Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma

Anna Babkova et al. Gynecol Oncol Rep. .

Abstract

The incidence of cancer during pregnancy is steadily rising because of the postponement of plans for childbearing. One of the most common cancers diagnosed during pregnancy is cervical cancer. Diagnosis of most cases usually occurs in the early stages, but there are still cases of tumors staged IB2 and higher. In these cases, the treatment strategy entails administration of neoadjuvant chemotherapy. However, a universally recognized standardized regimen for neoadjuvant chemotherapy treatment of cervical cancer during pregnancy has yet to be established. The chemotherapy agents used during treatment are known for their fetal adverse effects. The aim of the therapy is to attain full-term pregnancy while minimizing fetal toxicity and decreasing tumor size. In this case report, we present a first-time sequential chemotherapy administration to minimize the cumulative toxicity of individual regimens and demonstrate the benefits for the patient and fetus.

Keywords: Cervical cancer; Individualized therapy; Neoadjuvant chemotherapy; Pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Colposcopy at the time of the diagnosis (Archive of University Hospital Kralovske Vinohrady).
Fig. 2
Fig. 2
MRI and US at the time of the diagnosis (Archive of University Hospital Kralovske Vinohrady).
Fig. 3
Fig. 3
MRI and US after three cycles of chemotherapy (Archive of University Hospital Kralovske Vinohrady).
See this image and copyright information in PMC

References

    1. Al-Saleh E., Al-Harmi J., Nandakumaran M., Al-Shammari M. Transport kinetics of cisplatin in the perfused human placental lobule in vitro. J Matern Fetal Neonatal Med. 2008 Oct;21(10):726–731. - PubMed
    1. Amant F., Berveiller P., Boere I.A., Cardonick E., Fruscio R., Fumagalli M., et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019 Oct 1;30(10):1601–1612. - PubMed
    1. Babkova A., Rob L., Kubecova M., Hruda M., Halaska M.J. Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy. Acta Obstet Gynecol Scand. 2024 Apr;103(4):660–668. - PMC - PubMed
    1. Barr JJ, Mari G. Cerebral Blood Flow Velocity Waveforms and Fetal Anemia. In: Maulik D, Lees CC, editors. Doppler Ultrasound in Obstetrics and Gynecology [Internet]. Cham: Springer International Publishing; 2023 [cited 2024 Jan 7]. p. 297–311. Available from: https://doi.org/10.1007/978-3-031-06189-9_18.
    1. Bernardini F., Ferrandina G., Ricci C., Fagotti A., Fanfani F., Cavaliere A.F., et al. Neoadjuvant Chemotherapy in Pregnant Patients with Cervical Cancer: A Monocentric Retrospective Study. Curr Oncol. 2022 Aug 14;29(8):5702–5714. - PMC - PubMed

Publication types

LinkOut - more resources